MaaT Pharma Advances Toward Commercialization And Submits Marketing Authorization Application to the European Medicines Agency (EMA) for Xervyteg ® (MaaT013) in Acute Graft-versus-Host Disease

MaaT Pharma has submitted a Marketing Authorization Application (MAA) to the EMA for Xervyteg®, a microbiota therapeutic for acute Graft-versus-Host Disease (aGvHD) following two prior lines of therapy. The application is based on positive data from the ARES study, which demonstrated a 62% gastrointestinal overall response rate at Day 28, significantly exceeding expectations, and supported by data from an ongoing Early Access Program showing increased demand. If approved, Xervyteg® would be the first EMA-approved microbiota therapeutic and the first globally for hemato-oncology, potentially launching commercially in 2026 through a strategic partnership.

Analysis

MaaT Pharma has achieved a significant regulatory milestone by submitting a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead product candidate, Xervyteg® (MaaT013). This therapy targets adult patients with acute Graft-versus-Host Disease (aGvHD) involving gastro-intestinal issues who have failed two prior lines of therapy, positioning Xervyteg® to potentially become the first EMA-approved microbiota therapeutic and the first globally for a hemato-oncology indication. The submission addresses a critical unmet medical need, as current third-line aGvHD patients face a dismal prognosis with an 85% one-year mortality rate. The MAA is robustly supported by positive results from the pivotal ARES study, which reported a 62% gastrointestinal overall response rate (GI-ORR) at Day 28, significantly exceeding the 38% expected efficacy threshold, and an overall response rate across all organs of 64%. Notably, the study indicated a 12-month survival probability of 54% for Xervyteg® treated patients, a substantial improvement over the 15% historical survival for this refractory population. Complementing these findings, data from the ongoing Early Access Program (EAP) showed a 75% increase in physician demand for Xervyteg® in 2024 and demonstrated its capture of 25% of the addressable market in France. An independent Data Safety Monitoring Board also confirmed a favourable benefit/risk ratio for Xervyteg®. MaaT Pharma anticipates a potential commercial launch in 2026, contingent on EMA approval expected in H2 2026, and is actively pursuing strategic partnerships to facilitate broad market access.

Key Decisions for Investors

• The MAA submission for Xervyteg® represents a key valuation inflection point for MaaT Pharma; investors should monitor the EMA review process closely for potential approval in H2 2026, which could establish Xervyteg® as a first-in-class therapy.
• Given the strong ARES trial results, including a 62% GI-ORR and a 54% 12-month survival rate, alongside increasing EAP demand, investors should assess the significant market opportunity for Xervyteg® in addressing the high unmet need in third-line aGvHD.
• Upcoming catalysts, such as the release of final overall survival data in late H2 2025 and developments regarding strategic partnerships critical for the planned 2026 commercial launch, warrant careful attention for future value realization.